AAAAAA

   
Results: 1-9 |
Results: 9
New clinical trials for the treatment of neuroendocrine tumors
Authors: Bajetta, E Bichisao, E Artale, S Celio, L Ferrari, L Di Bartolomeo, M Zilembo, N Stani, SC Buzzoni, R
Citation: E. Bajetta et al., New clinical trials for the treatment of neuroendocrine tumors, Q J NUCL M, 44(1), 2000, pp. 96-101
Steroidal aromatase inhibitors in elderly patients
Authors: Bajetta, E Zilembo, N Bichisao, E Pozzi, P Toffolatti, L
Citation: E. Bajetta et al., Steroidal aromatase inhibitors in elderly patients, CR R ONC H, 33(2), 2000, pp. 137-142
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers
Authors: Martinetti, A Ferrari, L Celio, L Mariani, L Miceli, R Zilembo, N Di Bartolomeo, M Toffolatti, L Pozzi, P Seregni, E Bombardieri, E Bajetta, E
Citation: A. Martinetti et al., The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers, J STEROID B, 75(1), 2000, pp. 65-73
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors
Authors: Bajetta, E Zilembo, N Bichisao, E Martinetti, A Buzzoni, R Pozzi, P Bidoli, P Ferrari, L Celio, L
Citation: E. Bajetta et al., Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors, ANN ONCOL, 11(8), 2000, pp. 1017-1022
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
Authors: Kaufmann, M Bajetta, E Dirix, LY Fein, LE Jones, SE Zilembo, N Dugardyn, JC Nasurdi, C Mennel, RG Cervek, J Fowst, C Polli, A di Salle, E Arkhipov, A Piscitelli, G Miller, LL Massimini, G
Citation: M. Kaufmann et al., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial, J CL ONCOL, 18(7), 2000, pp. 1399-1411
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial
Authors: Bajetta, E Stani, SC De Candis, D Bidoli, P Mariani, L Zilembo, N Pozzi, P Procopio, G
Citation: E. Bajetta et al., Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial, CANCER, 89(4), 2000, pp. 763-768
Aromatase inhibitors in the treatment of postmenopausal breast cancer
Authors: Bajetta, E Zilembo, N Bichisao, E
Citation: E. Bajetta et al., Aromatase inhibitors in the treatment of postmenopausal breast cancer, DRUG AGING, 15(4), 1999, pp. 271-283
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Authors: Bajetta, E Zilembo, N Dowsett, M Guillevin, L Di Leo, A Celio, L Martinetti, A Marchiano, A Pozzi, P Stani, S Bichisao, E
Citation: E. Bajetta et al., Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients, EUR J CANC, 35(2), 1999, pp. 208-213
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
Authors: Bajetta, E Ferrari, L Martinetti, A Celio, L Procopio, G Artale, S Zilembo, N Di Bartolomeo, M Seregni, E Bombardieri, E
Citation: E. Bajetta et al., Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors, CANCER, 86(5), 1999, pp. 858-865
Risultati: 1-9 |